Fig. 3From: Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experienceThe overall survival for a chemo-naïve and b post-chemo mCRPC patients with or without visceral disease, and the progression-free survival for c chemo-naïve and d post-chemo mCRPC patients with or without visceral diseaseBack to article page